# Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

> **NCT07117760** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **First Affiliated Hospital of Fujian Medical University** · enrollment: 16 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 225Ac-LNC1011
- **DRUG:** 68Ga-PSMA-11

## Key facts

- **NCT ID:** NCT07117760
- **Lead sponsor:** First Affiliated Hospital of Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-22
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07117760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07117760, "Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07117760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*